^
Association details:
| Biomarker: | EFNB2 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma
Published date:
08/19/2022
Excerpt:
In this phase II trial, patients with metastatic urothelial carcinoma that recurred or progressed after platinum-based chemotherapy received soluble EphB4-human serum albumin (sEphB4-HSA) in combination with pembrolizumab….Forty-six (66%) patients expressed EphrinB2, and among them, the median OS was 21.5 months (95% CI, 12.4 to not reached), the ORR was 52% (95% CI, 37 to 67), including a complete response rate of 24% (11 of 46; 95% CI, 12 to 36).
Secondary therapy:
sEphB4-HSA
DOI:
10.1200/JCO.21.02923
